206 related articles for article (PubMed ID: 16509929)
1. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y
Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
[TBL] [Abstract][Full Text] [Related]
2. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal mapping of a quantitative trait locus for the development of albuminuria in diabetic KK/Ta mice.
Shike T; Gohda T; Tanimoto M; Kobayashi M; Makita Y; Funabiki K; Horikoshi S; Hirose S; Shirai T; Tomino Y
Nephrol Dial Transplant; 2005 May; 20(5):879-85. PubMed ID: 15769825
[TBL] [Abstract][Full Text] [Related]
5. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress.
Zhang M; Hagiwara S; Matsumoto M; Gu L; Tanimoto M; Nakamura S; Kaneko S; Gohda T; Qian J; Horikoshi S; Tomino Y
Metabolism; 2006 Dec; 55(12):1590-8. PubMed ID: 17142129
[TBL] [Abstract][Full Text] [Related]
6. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
[TBL] [Abstract][Full Text] [Related]
7. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
[TBL] [Abstract][Full Text] [Related]
8. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products.
Zheng F; He C; Cai W; Hattori M; Steffes M; Vlassara H
Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941
[TBL] [Abstract][Full Text] [Related]
9. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.
Hagiwara S; Makita Y; Gu L; Tanimoto M; Zhang M; Nakamura S; Kaneko S; Itoh T; Gohda T; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2006 Mar; 21(3):605-15. PubMed ID: 16282336
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
11. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic effect of hot-water extract of adzuki (Vigna angularis) in spontaneously diabetic KK-A(y) mice.
Itoh T; Kobayashi M; Horio F; Furuichi Y
Nutrition; 2009 Feb; 25(2):134-41. PubMed ID: 18929464
[TBL] [Abstract][Full Text] [Related]
13. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS
Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
[TBL] [Abstract][Full Text] [Related]
14. Influence of C-peptide on early glomerular changes in diabetic mice.
Maezawa Y; Yokote K; Sonezaki K; Fujimoto M; Kobayashi K; Kawamura H; Tokuyama T; Takemoto M; Ueda S; Kuwaki T; Mori S; Wahren J; Saito Y
Diabetes Metab Res Rev; 2006; 22(4):313-22. PubMed ID: 16389646
[TBL] [Abstract][Full Text] [Related]
15. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195.
Tsuchida K; Makita Z; Yamagishi S; Atsumi T; Miyoshi H; Obara S; Ishida M; Ishikawa S; Yasumura K; Koike T
Diabetologia; 1999 May; 42(5):579-88. PubMed ID: 10333051
[TBL] [Abstract][Full Text] [Related]
16. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.
Tanimoto M; Fan Q; Gohda T; Shike T; Makita Y; Tomino Y
Metabolism; 2004 Nov; 53(11):1473-9. PubMed ID: 15536604
[TBL] [Abstract][Full Text] [Related]
17. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.
Cha DR; Kim IS; Kang YS; Han SY; Han KH; Shin C; Ji YH; Kim NH
Diabet Med; 2005 Jan; 22(1):14-20. PubMed ID: 15606685
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice.
Murakoshi M; Tanimoto M; Gohda T; Hagiwara S; Ohara I; Toyoda H; Ishikawa Y; Horikoshi S; Tomino Y
Diabetes Res Clin Pract; 2009 Feb; 83(2):183-9. PubMed ID: 19144436
[TBL] [Abstract][Full Text] [Related]
19. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy.
Ninichuk V; Kulkarni O; Clauss S; Anders H-
Eur J Med Res; 2007 Aug; 12(8):351-5. PubMed ID: 17933712
[TBL] [Abstract][Full Text] [Related]
20. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.
Myint KM; Yamamoto Y; Doi T; Kato I; Harashima A; Yonekura H; Watanabe T; Shinohara H; Takeuchi M; Tsuneyama K; Hashimoto N; Asano M; Takasawa S; Okamoto H; Yamamoto H
Diabetes; 2006 Sep; 55(9):2510-22. PubMed ID: 16936199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
